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Abstract:  Andrographolide derivatives were shown to inhibit α-glucosidase. To 
investigate the relationship between activities and structures of andrographolide 
derivatives, a training set was chosen from 25 andrographolide derivatives by the principal 
component analysis (PCA) method, and a quantitative structure-activity relationship 
(QSAR) was established by 2D and 3D QSAR methods. The cross-validation r
2 (0.731) 
and standard error (0.225) illustrated that the 2D-QSAR model was able to identify the 
important molecular fragments and the cross-validation r
2 (0.794) and standard error 
(0.127) demonstrated that the 3D-QSAR model was capable of exploring the spatial 
distribution of important fragments. The obtained results suggested that proposed 
combination of 2D and 3D QSAR models could be useful in predicting the α-glucosidase 
inhibiting activity of andrographolide derivatives. 
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1. Introduction 
 
Andrographis paniculate is a plant widely used as a traditional Chinese medicine in China, India, 
and other Asian countries [1,2]. Extracts and constituents of Andrographis paniculate exhibit broad 
pharmacological activities, such as anti-bacterial, ant-malarial, anti-inflammatory, anti-tumor, 
immunological regulation, and hepatoprotective effects [3–12]. Lately, some andrographolide 
derivatives were reported to decrease blood glucose level by inhibiting α-glucosidase [13,14]. It has 
been well known that α-glucosidase is a key enzyme in the absorption of sugar in the small intestine 
mucous membrane, and its activity is closely related to blood glucose levels. Studies also indicated 
that α-glucosidase might be involved in diabetes
 [15–20]. Accordingly, α-glucosidase is considered an 
important target for the design of antidiabetic drugs. Recently, efforts had been made in modification 
and synthesis of novel andrographolide derivatives to find more potent and safer α-glucosidase 
inhibitors. Knowledge about the relationships between structures of andrographolide derivatives and 
their inhibitory activities on α-glucosidase could greatly facilitate the drug discovery process. 
QSAR [21] has been widely used for years to provide quantitative analysis of structure and activity 
relationships of compounds. Statistical methods are applied in QSAR modeling to establish 
correlations between chemical structures and their biological activities. Once validated, the findings 
can be used to predict activities of untested compounds. Recently, computer-assisted drug design 
based on QSAR has been successfully employed to develop new drugs for the treatment of cancer, 
AIDS, SARS, and other diseases [22–29]. With the availability of large commercial databases and 
highly efficient programs including Sybyl, Discovery studio, MOE and so on, it is estimated that 
QSAR modeling as a tool could remarkably reduces the cost of drug discovery [30].  
In this study, 2D QSAR models were constructed to describe the important fragments in 
andrographolide derivatives and 3D QSAR models were established to explore the spatial distribution 
of important groups. The combination of 2D and 3D QSAR models could better summarize the QSAR 
of andrographolide derivatives in inhibiting α-glucosidase. 
 
2. Computational Methods 
 
2.1. Database and Software 
 
The structures and inhibitory activities (IC50) of 25 andrographolide derivatives (Figure 1) were 
collected from the literature, and served as the database to build QSAR models [13,14,31]. PLogIC50 
was used as the dependent variable of QSAR model. PCA, HQSAR, CoMFA, CoMSIA were 
performed by Sybyl7.03 (Tripos Co., LTD) program. Int. J. Mol. Sci. 2010, 11                 
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Figure 1. Formulae of the studied andrographolide derivatives. 
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2.2. Training Set Selection  
 
Principle Component Analysis (PCA),
 employed to select the training set, could be applied to 
explain the differences among the 25 andrographolide derivatives through diversities of the structures’ 
parameters and to exhibit their distribution on a 2D plot [32]. Furthermore, the most descriptive 
compounds (MDC) or the largest minimum distance (LMD) methods were applied to select the 
training set according to the distribution of these compounds. 
 
2.3. Generation and Validation of the 2D QSAR Model 
 
Hologram QSAR (HQSAR) offers the ability to rapidly generate QSAR models of high statistical 
quality and predicted value by SYBYL line notation (SLN), cyclic redundancy check (CRC) and Int. J. Mol. Sci. 2010, 11                 
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partial least squares (PLS) [33–35]. The premise of HQSAR is that since the structure of a molecule is 
encoded within its 2D fingerprint and that structure is the key determinant of all molecular properties 
(including biological activity), it should be possible to predict the activity of a molecule from its 
fingerprint. 
The training set was used to establish 2D-QSAR model by HQSAR, and the best 2D-QSAR model 
was applied by the criterion of cross-validation R
2. The test set’s biological activity was predicted by 
the best 2D-QSAR model, whose predictability was validated by correlation coefficient between the 
predicted and experimental values. The most common structure (MCS) could be calculated by 
HQSAR. Based on the MCS of andrographolide derivatives, the contributions of molecules’ fragments 
to biological activity should be analyzed for describing the QSAR of andrographolide derivatives as  
α-glucosidase inhibitors. 
 
2.4. Generation and Validation of the 3D QSAR Model 
 
The three-D QSAR model applies PLS
 to explore the relationships between the physicochemical 
variables and biological activity. Cross-validation is used to estimate the QSAR model’s predictability. 
In general, a LOO cross-validated coefficient Q
2 (higher than 0.5) can be considered as statistically 
high predictive ability [36]. CoMFA, which is widely utilized in 3D-QSAR research, claims that if a 
group of similar compounds are ligands of the same receptor, their bioactivities depend on the 
differences of the molecules’ fields surrounding them [37]. CoMFA can exhibit a contour map in a 3D 
graph, which makes it easier to distinguish differences between compounds with strong and weak 
activities. CoMSIA is another 3D-QSAR method that adopts a Gaussian function instead of traditional 
Coulomb and Lennard-Jones’ function used in CoMFA [38]. Therefore, CoMSIA efficiently avoids 
the shortcomings of CoMFA in which only the steric and electrostatic fields are used. The leave-one-
out (LOO) method is employed to validate the predictability of the models and Y-Randomization test 
is used to validate the robustness of the models [39].  
In this study, CoMFA and CoMSIA were both utilized to generate 3D-QSAR models, and then the 
relative higher predictive 3D-QSAR models were selected by comparison. Subsequently, the selected 
models were further optimized by the Focusing method [40]. This method describes the different 
contributions of different grids in CoMFA and CoMSIA to the bioactivities of the compounds by 
weighting, which was expected to selectively enhance or impair the contributions of different grids and 
improve the resolution. Moreover, the biological activities of test set were predicted by the optimized 
QSAR model. The best QSAR model was determined by comparing the parameters of the model and 
correlation between the predicted and experimental values of the test sets. 
 
3. Result and Discussion 
 
3.1. Training Set Selection 
 
The selection of the training set is one of the most important steps in QSAR modeling, since the 
establishment and optimization of a QSAR model are based on this training set. Predictability and 
applicability of a QSAR model also depend on the training set selection [41,42]. Usually, the Int. J. Mol. Sci. 2010, 11                 
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compounds serving as the training set should have three characteristics: (1) maximum structural 
diversity; (2) maximum activity diversity; (3) similarity of interactions [43]. Besides, both molecular 
structures and biological activities of the test set should be covered by the ranges of the training set. In 
this research, PCA
 was applied to select a training set from among 25 andrographolide derivatives. 
PCA is a statistical technique useful for summarizing all the information encoded in the structures of 
compounds. It is also very helpful for understanding the distribution of the compounds.  
The distribution pattern of the 25 andrographolide derivatives is shown in Figure 2. There were 
different population densities in the Figure. Eighteen compounds (1, 3–8, 11, 13, 16–21 and 23–25) 
were selected as the raining set by the MDC method. The rest of them (compounds 2, 9, 10, 14, 15 and 
22) were used as the test set whose biological activities were covered by the training set. 
Figure 2. PCA plot for studied compounds 1–25. 
 
 
3.2. Establishment and Validation of 2D-QSAR Model 
 
The best cross-validation r
2 (0.731) and standard error (0.225) illustrated that the 2D-QSAR model 
could be applied to predict the biological activity of andrographolide derivatives as α-glucosidase 
inhibitors. The predicted and experimental biological activities of andrographolide derivatives are 
shown in Table 1. The results of the correlation coefficient R
2, standard error of the training set (0.840, Int. J. Mol. Sci. 2010, 11                 
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0.174) and test set (0.949, 0.104) suggested that the 2D-QSAR model could be used to explain the 
QSAR of andrographolide derivatives as α-glucosidase inhibitors. 
Table 1. Comparison of the predicted PLogIC50 of database with the experimental values 
by using 2D-QSAR Model. 
Compound ACT
a   PRE
b | ∆|
c  Compound  ACT   PRE   |∆| 
1  4.000  3.933 0.067 2  4.000 3.995 0.05 
3  3.959  3.876 0.109 4  3.959 4.054 0.095 
5 -  -  -
d 6  4.237  4.139  0.098 
7  4.237  4.159 0.078 8  4.076 4.087 0.011 
9  4.155  4.061 0.094 10  4.000 4.099 0.099 
11 4.000  4.089  0.089  12 -  -  -
d 
13  3.959  4.176 0.217 14  4.000 3.946 0.054 
15  3.983  3.924 0.059 16  3.921 3.961 0.040 
17  3.996  3.954 0.042 18  3.971 3.902 0.069 
19  4.553  4.686 0.133 20  4.796 4.813 0.017 
21  5.222  4.806 0.416 22  4.854 4.798 0.056 
23  4.602  4.715 0.113 24  4.444 4.745 0.301 
25 4.959  4.698  0.261         
a: Experimental data (PLogIC50) 
b: Predicted data (PLogIC50) 
c: |a-b| 
d: Outline compounds. 
 
Furthermore, three key fragments (Figure 3) were selected according to PLS coefficient. The 
predicted activity =    
i
i i b C C ) ( 0  where C0 = the offset, Ci = the PLS coefficient associated with 
bin I in the hologram, bi = the number of fragments hashed into bin i. 
Figure 3. Key fragments of 2D-QSAR Model. 
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The PLS coefficient was the standardization for judging which fragment was the key fragment. The 
larger the PLS coefficient, the more important the fragment was for andrographolide derivatives’ 
biological activity. According to the criterion, C (=C©C)C=C or C[1]:C:C:C(:C:C:@1)C=C attached 
to C3 of andrographolide (Figure 4) and C[1]:N:C:C(:C:C:@1)C(=C)O attached to C17 of 
andrographolide were suggested as the key fragments. 
Figure 4. Structure of andrographolide. 
 
 
3.3. Establishment and Validation of the 3D-QSAR Model 
 
The 18 compounds were energy minimized, added charges and aligned (Figure 5). CoMFA and 
CoMSIA were used to develop a number of QSAR models based on the properties of compounds 
belonging to different fields (steric, electrostatic, hydrophobic, H-donor and acceptor, Table 2). Since 
the QSAR model was employed to predict unknown compounds’ activity, the model’s predictability 
was the criterion to judge which QSAR model was the best. Predictability of a QSAR model was not 
only expressed by cross-validation (q
2) but also by validation of the test set. The results illustrated that 
four models (4, 8, 10 and 11) had the top four predictabilities, so the Focus method was then applied to 
optimize these models, and further improved predictability for model 4, 10 and 11, but not for model 8. 
Among these models (model 8, 13, 15 and16), model 16 exhibited the best predictability as indicated 
by the highest Q2 value. Predictability of these models (8, 13, 15 and 16) was further evaluated using a 
test set. Model 16 also provided the best prediction with a correlation coefficient R
2 (0.941) (Table 3). 
Overall, this model represented the best QSAR model (q
2 = 0.794, R
2
cv = 0.915, SEcv = 0.127,   
R
2
test set = 0.941, SEtest set = 0.104). Y-Randomization test (q
2 = 0.199) suggested that the model also 
had a good robustness. Table 4 showed Comparison between predicted PLogIC50 of database and 
experimental values by using Model 16. Int. J. Mol. Sci. 2010, 11                 
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Figure 5. Alignment of the database. 
 
Table 2. Comparison of different 3D-QSAR models. 
No. Method  Field
a OC
b (q
2)
c SE
d (R
2)
e F 
1 CoMFA  S+E  1  0.741  0.178  0.819  67.905 
2  
 
 
 
 
 
CoMSIA 
 
 
S 2  0.748  0.159  0.866  45.280 
3 E  1  0.710  0.187  0.802  60.592 
4 H  2  0.771  0.132  0.907  68.505 
5 D  1  0.313  0.297  0.498  14.876 
6 A  1  0.724  0.184  0.807  62.902 
7 S+E  1  0.732  0.182  0.812  64.778 
8 S+H  1  0.774  0.148  0.875  105.050 
9 S+A  2  0.738  0.159  0.866  45.251 
10 S+E+H  1  0.755  0.169  0.838  77.788 
11 S+H+A  2  0.759  0.130  0.910  70.509 
12 S+E+H+A  1  0.747  0.174  0.829  72.588 
13
f H(Focus)  1  0.776  0.144  0.882  112.028 
14
f S+H(Focus)  2  0.772  0.1.43  0.891  57.188 
15
f S+E+H(Focus)  2  0.763  0.148  0.884  53.422 
16
f S+H+A(Focus)  2  0.794  0.127  0.915  75.093 
 Y-Random  S+H+A(Focus)  1  0.199  -  -  - 
a: S: Steric field, E: Electrostatic field, H: Hydrophobic field. 
D: H-donor field, A: H-acceptor field. 
b: Optimum of component. 
c: The models’ cross-validation r
2. 
d: Standard Error. 
e: Correlation coefficient between predicted and experimental PLogIC50 of 18 compounds. 
f: The model was optimized by Focus Method. Int. J. Mol. Sci. 2010, 11                 
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Table 3. Correlation coefficient between predicted and experimental PLogIC50 of the test 
set by model 13, 8, 15, and 16. 
No. Models  R
2 Slope  SE 
13  H(Focus)  0.906 1.007 0.143 
8  S+H  0.927 0.974 0.121 
15  S+E+H(Focus)  0.895 0.937 0.142 
16  S+H+A(Focus) 0.941 0.933 0.104 
Table 4. Comparison between predicted PLogIC50 of database and experimental values by 
using Model 16. 
Compound ACT
a   PRE
b | ∆|
c  Compound  ACT   PRE   |∆| 
1 3.996  3.960  0.04  2 4.000  3.960  0.04 
3  3.959  3.970 0.011 4  3.959 3.999 0.04 
5 -  -  -
d 6  4.237  4.238  0.001 
7  4.237  4.204 0.033 8  4.076 4.016 0.06 
9  4.155  4.179 0.029 10  4.000 4.119 0.119 
11 4.000  3.935  0.065  12 -  -  - 
13  3.959  4.111 0.152 14  4.000 4.150 0.150 
15  3.983  4.112 0.129 16  3.921 4.075 0.154 
17 3.996  3.916  0.08  18 3.971  3.903  0.068 
19  4.553  4.621 0.068 20  4.796 4.863 0.068 
21  5.222  5.067 0.155 22  4.854 4.886 0.032 
23  4.602  4.831 0.229 24  4.444 4.481 0.037 
25 4.959  4.698  0.261         
a: Experimental data (PLogIC50) 
b: Predicted data (PLogIC50) 
c: |a−b| 
d: Outline compounds 
 
Model  16 used steric field, hydrophobic field and H-acceptor field together to describe the 
relationship between activities and structures of andrographolide derivatives. H-bond receptive atoms 
and groups in the region marked by blue lines (Figure 6) were favorable for the activities of the 
compounds, while the atoms and groups in the region marked by yellow lines impaired the activities. 
Hydrophobic groups were desirable in the region marked with blue lines but not the region marked by 
dark lines (Figure 7). In addition, the activities of the andrographolide derivatives were enhanced by 
the presence of steric groups in the region marked by purple lines instead of the region marked by 
green lines (Figure 8). The compounds with structures fitting well into the 3D contour maps derived 
from the model 16 usually exhibited potent inhibitory activity (e.g., compounds 20, 21, 22 and 23). In 
contrast, weak inhibitors such as compounds 3,  4,  13 and 16 did not have a good fit to the 3D   
contour maps.  Int. J. Mol. Sci. 2010, 11                 
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Figure 6. Compound 21 placed in the H-accept contour map. 
 
Figure 7. Compound 21 placed in the hydrophobic contour map. 
 
Figure 8. Compound 21 was placed in the steric contour map. 
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Compound 21 (potent α-glucosidase inhibitor PLogIC50 = 5.222) was layed in the 3D contour maps 
of model 16 to illustrate the key groups (marked by red dashed lines in Figures 5, 6, and 7) correlating 
with biological activity. C[1]:N:C:C(:C:C:@1)C(=C)O was a key group in all the 3D contour maps 
(steric, H-accept, hydrophobic) and C[1]:C:C:C(:C:C:@1)C=C was a key group in both steric and 
hydrophobic 3D contour maps. Both the groups were also calculated as key groups in HQSAR. 
Combining the results of HQSAR and CoMSIA, the two groups were considered as the key groups 
associated with biological activity and the result can also be used to screen potent α-glucosidase 
inhibitors from various databases by virtual screening. 
4. Conclusions  
In our research, 2D QSAR and 3D QSAR models have been successfully established to 
quantitatively describe the relationship between structures and activities of andrographolide 
derivatives as α-glucosidase inhibitors. The 2D QSAR model was based on the atomic connection of 
molecules and suggested that there might be three key groups associated with biological activity. 
Furthermore, the 3D QSAR model was based on molecular properties belonging to steric, hydrophobic 
and H-acceptor fields and indicated that compounds with structures fitting better into the 3D contour 
maps of model 16 had more potent activities. Combining 2D and 3D QSAR models, the key fragments 
and their spatial distribution could be efficiently identified. The convinced predictability of the model 
was demonstrated not only by internal validation but also by external validation using a test set. 
Overall, these results suggested that the developed QSAR model could be used to predict the 
inhibitory activities of unknown andrographolide derivatives on α-glucosidase. Application of this 
model would greatly facilitate the discovery of better α-glucosidase inhibitors. 
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